Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Aug

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

ACS Study Quantifies Financial Burden of Cancer in Older Patients

Transplant Consolidation Improves Survival in Primary CNS Lymphoma

Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL

NCI Names New CCR Director

Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy